Synthekine

Private

Menlo Park, CaliforniaHealthcare & Life Scienceshttps://www.synthekine.com

Last Round

Series C

Jan 6, 2023

Total Funding Raised

$289.5M

Momentum

Quiet

No recent growth signals

Company Overview

Synthekine is a biotechnology company that develops engineered cytokine therapeutics aimed at creating disease-optimized treatments through targeted protein engineering and immunological insights for cancer and autoimmune disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

engineered cytokinescytokine therapeuticsimmuno-oncologyI-Oautoimmune disease treatmentprotein engineeringIL-2 therapeuticsalpha/beta biased IL-2cytokine partial agonistIL-10 receptor agonistIL-12 therapeuticsbiased agonistcytokine-enhanced cell therapyorthogonal cytokinesCAR-T combination therapybiopharmaceutical partnershipsdrug licensingclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Synthekine Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Synthekine Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Series C	Jan 6, 2023
Series B	Jun 10, 2021
Series A	Sep 17, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Greg Yedinak

Chief Technology Officer

Executive Team

Synthekine Investors

Notable investors and investment history

Investor	Rounds
The Column Group	Series B, Series C, Series A
Deerfield Management	Series C, Series B
Janus Henderson Group	Series C, Series B
RA Capital Management	Series C, Series B
Omega Funds	Series C, Series B
The Chernin Group	Series B, Series C, Series A
Canaan Partners	Series C, Series B, Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Oct 31, 2025
Presenting initial clinical data for STK-012 at SITC 2025.
Oct 31, 2025
Initial data for STK-012 will be presented at SITC 2025.

View all signals

Synthekine Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Synthekine Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Synthekine's valuation, stock price, and market status.

Firmographic Details

HeadquartersMenlo Park, California

Employee Range70

Year Founded2018

Last FundingJan 6, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.